BRUKER CORP
Nasdaq: BRKR·Billerica, Massachusetts·CIK 0001109354
- Price
- $60.62
- Base IV
- $29.56
Valuation snapshot
At $60.62, the price is above even our bull case of $45.97.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $29.56
- 49% of the price · range $9.74–$45.97
- Price vs base case
- 105% above
- $60.62 against $29.56
- Base case · our researched forecast, 2026-11-06See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has risen 4.4% since this valuation was struck on 2026-11-06, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $9.74 to bull $45.97. Values per share.
Price against each value
- Bear case
- $9.74
- Price 522% above
- No growth
- …
- —
- Base case
- $29.56
- Price 105% above
What does Bruker do?
It brought in $3.5B of sales in the 12 months to Sep 2026.
- Industry
- Semiconductors
- Based in
- Billerica, Massachusetts
- Trades on
- Nasdaq as BRKR
Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $1.04, so it lost 4¢ on each dollar. The biggest cost is making what it sells, 52¢ of every dollar.
- Making what it sells52¢
- Research and development11¢
- Sales, marketing and admin27¢
- Everything else it takes to operate11¢
- Tax1¢
- Lost on each dollar−4¢
Who pays Bruker, and for what?
Bruker develops, manufactures, and sells advanced scientific instruments and diagnostic systems. Customers use its equipment to examine molecules, cells, and microscopic materials in detail. The company generates revenue by selling these high-tech machines and providing ongoing maintenance, replacement parts, and software.
Customers include universities, government research agencies, pharmaceutical and biotechnology companies, hospitals, and industrial manufacturers.
BSI CALID
35%Produces mass spectrometry, molecular spectroscopy, and diagnostic systems used in life science research, clinical microbiology, infectious disease testing, and food safety.
Bruker MALDI Biotyper mass spectrometerSpicy, CC BY-SA 4.0, via Wikimedia Commons BSI NANO
32%Provides advanced X-ray tools, atomic force microscopes, optical imaging, and spatial biology systems to analyze materials and single cells at the nanoscale.
Bruker D8 ADVANCE X-ray diffractometerImage: Bruker BSI BioSpin
26%Supplies magnetic resonance systems, including high-field nuclear magnetic resonance spectrometers and preclinical animal scanners, alongside laboratory automation software.
Bruker Avance NEO NMR spectrometer systemImage: Bruker BEST
8%Manufactures metallic superconducting materials and specialized scientific tools used in clinical MRI machines, fusion energy projects, and particle physics research.
Where its work physically happens, beyond headquarters:
- Bruker Fällanden site — Fällanden, Switzerland. This BSI BioSpin site supports magnetic resonance and preclinical imaging, and also houses a smaller leased BSI CALID mass spectrometry operation, so it underpins Bruker's high-end research instrument franchise.
- Bruker Bremen mass spectrometry site — Bremen, Germany. At about 272,743 sq ft and owned, this is the largest clearly reported site in the 10-K property table and anchors mass spectrometry for the BSI CALID segment.
- Bruker Hanau superconductor site — Hanau, Germany. This owned site of about 258,872 sq ft serves the energy and superconducting business, whose superconducting materials go to MRI, NMR and fusion energy research customers.
- Bruker Ettlingen site — Ettlingen, Germany. Two owned facilities here, about 215,385 sq ft for BSI CALID mass spectrometry and CBRNE detection and about 179,399 sq ft for BSI BioSpin preclinical imaging, make it a multi-segment operating hub.
- Bruker Wissembourg site — Wissembourg, France. This owned BSI BioSpin site of about 219,745 sq ft supports magnetic resonance and preclinical imaging, adding capacity to the segment's core product lines.
Bruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
How is the business doing?
Sales grew from $2B in 2020 to $3.4B in 2025, about 12% a year.
It spends more to run the business than it brings in: an operating loss of 2¢ per sales dollar.
After paying for its upkeep and new investment, it had $244.7M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Bruker aims to empower scientists and researchers to make breakthrough discoveries and create tools that improve human health and the environment.
“Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.”
What management says it is working on now:
Executing Corporate Cost Reductions
Management is implementing structural cost-cutting programs across supply chains, manufacturing, and general corporate administration to expand profit margins.
Bruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025Integrating Acquired Businesses
Management is integrating acquisitions such as ELITechGroup and NanoString to scale its molecular diagnostics and spatial biology portfolios.
Bruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025Growing Aftermarket and Service Revenue
The company is focusing on expanding connected services, software workflows, and consumable kit sales to increase predictable recurring revenue.
Bruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025Commercializing Ultra-High-Field Instruments
Bruker is advancing access to its flagship ultra-high-field nuclear magnetic resonance spectrometers and benchtop instruments to support structural biology.
Bruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
- Annualized cost savings, by the end of 2026
- $120 million to $140 million
- Bruker Reports Second Quarter 2026 Financial Results
- Full-year revenue, FY 2026
- $3.54 billion to $3.57 billion
- Bruker Reports Second Quarter 2026 Financial Results
- Non-GAAP effective tax rate, FY 2026
- approximately 27.5%
- Bruker Reports Second Quarter 2026 Financial Results
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 2% more than a year earlier. The year before, quarters averaged 2%.
Its operating margin is narrower than a year ago: a loss of 10¢ per sales dollar, against a loss of 6¢.
Since Nov 2026 the share price has risen 9%, from $55.69 to $60.62.
Recently
December 31, 2024
Annual BSI CALID segment revenue changed to $1.1B
Bruker Corporation 2024 Form 10-K Note 18 Segment InformationDecember 31, 2024
Annual organic revenue growth changed to 4.0%
Bruker Corporation 2024 Form 10-K
Coming up
November 4, 2026
Q3 2026 Earnings Announcement and Webcast
Bruker will announce its third quarter 2026 operating results and discuss book-to-bill trends and full-year guidance adjustments.
Bruker Investor Relations Events CalendarEnd of 2026
Completion of Corporate Cost Reduction Program
The company expects to reach its annualized operational cost savings run rate of $120 million to $140 million across global functions.
Bruker Reports Second Quarter 2026 Financial ResultsFourth quarter of 2026
Semiconductor Metrology Deliveries Ramp
Approximately $20 million of delayed semiconductor tool orders are scheduled to complete and deliver to customers, aiding fourth-quarter revenue.
Bruker Second Quarter 2026 Earnings Conference Call
Our own estimate moved too: the base case went from $15.98 to $29.56 a share between our last two valuations. The biggest reason: Annual BSI CALID segment revenue moved from an unreported prior value to $1.1B, as reported in Bruker Corporation 2024 Form 10-K Note 18 Segment Information.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Import and Reciprocal Tariffs
New and shifting tariffs increase manufacturing costs on imported parts and reduce customer purchasing power, which depresses gross margins and sales volumes.
From the company's own filingsWould hit how much of each sale it keepsBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
Academic and Government Funding Reductions
A substantial portion of customers depend on government research grants, and budget cuts or delays cause laboratories to postpone buying major instruments.
From the company's own filingsWould hit how fast sales growBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
China Demand and Stimulus Delays
Delays in the release of Chinese government stimulus spending for medical and industrial research instrumentation have dampened instrument sales growth in China.
From the company's own filingsWould hit how fast sales growBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
Supply Chain and Single-Source Component Shortages
The company relies on single-source suppliers for certain specialized components, and parts shortages or production delays create manufacturing inefficiencies and raise costs.
From the company's own filingsWould hit how much of each sale it keepsBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
Goodwill and Intangible Asset Impairment
Downturns in acquired businesses or higher market uncertainty can force write-downs of intangible assets, directly lowering reported operating profits.
From the company's own filingsWould hit how much it has to reinvestBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
Rapid Technological Change and Competition
If larger competitors develop faster, lower-cost, or more advanced analytical instruments, Bruker's products could become obsolete or lose pricing power.
From the company's own filingsWould hit its growth in the long runBruker Corporation Form 10-K for the Fiscal Year Ended December 31, 2025
Revenue growth stalled to 2.08% in 2025 and 1.57% in Q3 2026 due to cyclical life sciences spending headwinds.
From our researchWould hit how fast sales growBruker Q3 2026 Form 10-Q
Q2 and Q3 2026 GAAP operating margins were -7.79% and -10.41% respectively, burdened by non-cash intangible asset amortization.
From our researchWould hit how much of each sale it keepsBruker Q3 2026 Financial Release
Is it a good business?
From 2016 to 2025 it earned between 1% and 22% on the capital invested in it, a median of 18%. Its cost of capital in the latest valuation is 9.0%; returns were above it in 8 of the 10 years.
From 2016 to 2025 it earned between -0% and 31% on its shareholders' equity, a median of 21%.
Over 10 years its operating margin ranged from 2¢ to 17¢ per sales dollar, a median of 13¢. Gross margin ran from 46¢ to 52¢.
Cost of capital 9.0%
The number of shares has held roughly steady over the past year.
It owes $1.6B more than it holds in cash. The latest four quarters had no positive operating profit to compare with that debt.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $60.62. Our put its value between $9.74 and $45.97, with $29.56 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $9.74
After significant acquisition spending and recent quarterly operating losses, this scenario assumes ongoing university and pharmaceutical budget constraints keep sales growth near 2% while profitability recovers only to high single-digit levels.
Base case, $29.56
This scenario anticipates that core demand for specialized scientific tools recovers to historical mid-single-digit sales growth while aggressive operational cost savings return profitability to healthy mid-teen levels.
Bull case, $45.97
This scenario envisions a strong rebound fueled by expanding biotechnology budgets and rapid commercial scaling in spatial biology and automated diagnostics, lifting profitability back toward 19%.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 105%
For Bruker to be worth today's $60.62, sales would need to grow about 19.7% a year. We assume 5.6%. Over the last 5 years, sales grew 8.3% a year.
Or, if sales grow 5.6% as we assume, the price works with a profit margin of 27.5% (we assume 15.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 19.7% a year?
Try your own numbersWe're moderately sure of this range: it scores 59 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $29.56 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.6%
- Operating margin15.5%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$29.56 -51.2%


